You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Claims for Patent: 11,590,136

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,590,136

Title:	Topical formulation for a JAK inhibitor
Abstract:	This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Inventor(s):	Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Assignee:	Incyte Corp , Incyte Holdings Corp
Application Number:	US17/704,180
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,590,136
Patent Claims:	1. A method of treating a skin disorder in a human patient in need thereof comprising: applying to the patient's skin a pharmaceutically composition comprising: 1) a therapeutic agent present in an amount ranging from about 0.5% to about 1.5% by weight of the composition, wherein the therapeutic agent is (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile or a pharmaceutically acceptable salt thereof, and (2) a means for effecting skin permeation of (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile to the patient, wherein the treating step is one or more of (a) inhibiting the skin disorder and (b) ameliorating the skin disorder. 2. The method according to claim 1, wherein the applying step comprises application up to 84 consecutive days to the patient's skin. 3. The method according to claim 1, wherein the applying step is repeatable. 4. The method according to claim 1, wherein the applying step comprises daily application to the patient's skin. 5. The method according to claim 1, wherein the skin disorder is an autoimmune skin disorder. 6. The method according to claim 1, wherein the skin disorder is associated with JAK1 and/or JAK2. 7. The method according to claim 1, wherein the skin disorder is chosen from pemphigus vulgaris (PV), bullous pemphigoid (BP), psoriasis, psoriasis vulgaris, atopic dermatitis, and combinations thereof. 8. The method according to claim 1, wherein the skin disorder is atopic dermatitis. 9. The method according to claim 1, wherein the therapeutic agent is (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphoric acid salt. 10. A method of treating a skin disorder in a human patient in need thereof comprising: applying to the patient's skin a pharmaceutical composition comprising: (1) a therapeutic agent present in an amount of about 0.5% by weight of the composition, wherein the therapeutic agent is (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile or a pharmaceutically acceptable salt thereof, and (2) a means for effecting skin permeation of (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile to the patient, wherein the treating step is one or more of (a) inhibiting the skin disorder and (b) ameliorating the skin disorder. 11. The method according to claim 10, wherein the skin disorder is an autoimmune skin disorder. 12. The method according to claim 10, wherein the skin disorder is associated with JAK1 and/or JAK2. 13. The method according to claim 10, wherein the skin disorder is chosen from pemphigus vulgaris (PV), bullous pemphigoid (BP), psoriasis, psoriasis vulgaris, atopic dermatitis, and combinations thereof. 14. The method according to claim 10, wherein the skin disorder is atopic dermatitis. 15. The method according to claim 10, wherein the therapeutic agent is (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphoric acid salt. 16. A method of treating a skin disorder in a human patient in need thereof comprising: applying to the patient's skin a pharmaceutical composition comprising: (1) a therapeutic agent present in an amount of about 1.0% by weight of the composition, wherein the therapeutic agent is (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile or a pharmaceutically acceptable salt thereof, and (2) a means for effecting skin permeation of (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile to the patient, wherein the treating step is one or more of (a) inhibiting the skin disorder and (b) ameliorating the skin disorder. 17. The method according to claim 16, wherein the skin disorder is an autoimmune skin disorder. 18. The method according to claim 16, wherein the skin disorder is associated with JAK1 and/or JAK2. 19. The method according to claim 16, wherein the skin disorder is chosen from pemphigus vulgaris (PV), bullous pemphigoid (BP), psoriasis, psoriasis vulgaris, atopic dermatitis, and combinations thereof. 20. The method according to claim 16, wherein the skin disorder is atopic dermatitis. 21. The method according to claim 16, wherein the therapeutic agent is (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphoric acid salt. 22. A method of treating a skin disorder in a human patient in need thereof comprising: applying to the patient's skin a pharmaceutical composition comprising: (1) a therapeutic agent present in an amount of about 1.5% by weight of the composition, wherein the therapeutic agent is (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile or a pharmaceutically acceptable salt thereof, and (2) a means for effecting skin permeation of (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile to the patient, wherein the treating step is one or more of (a) inhibiting the skin disorder and (b) ameliorating the skin disorder. 23. The method according to claim 22, wherein the skin disorder is an autoimmune skin disorder. 24. The method according to claim 22, wherein the skin disorder is associated with JAK1/JAK2. 25. The method according to claim 22, wherein the skin disorder is chosen from pemphigus vulgaris (PV), bullous pemphigoid (BP), psoriasis, psoriasis vulgaris, atopic dermatitis, and combinations thereof. 26. The method according to claim 22, wherein the skin disorder is atopic dermatitis. 27. The method according to claim 22, wherein the therapeutic agent is (R)-3-cyclopentyl-3-[4 (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphoric acid salt.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.